RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report third quarter 2025 financial results on November 5, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to disc ...

Group 1 - The article discusses the frequent discussions of specific covered call trades within The Biotech Forum, highlighting the investment strategies employed by the group [1] - The portfolio composition includes a significant allocation of nearly 25% in short-term treasuries and cash, indicating a cautious market outlook [1] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly market commentary [1] Group 2 - The analyst has disclosed a beneficial long position in several biotech stocks, including ADMA, HRMY, SNDX, and XBI, indicating a vested interest in these companies [2] - The article emphasizes that past performance does not guarantee future results, reflecting a common disclaimer in investment analysis [3]

Group 1: Market Overview - The stock market experienced high volatility in Q2 2025, with a 7% drop in stock prices from April 2 to April 7 due to an unexpected tariff announcement [1] - Following the Trump Administration's retreat from extreme tariff proposals, the market saw a dramatic recovery, supported by sound corporate earnings and solid economic data indicating positive growth ahead [1] - The Russell 2000 Growth Index rallied in Q2 2025, and the Renaissance Investment Small Cap Growth Strategy outperformed this index [1] Group 2: ADMA Biologics, Inc. Overview - ADMA Biologics, Inc. is a commercial-stage biopharmaceutical company focused on plasma-based biologics for immune deficiencies and infectious disease prevention [3] - The company has a significant product, Asceniv, which addresses primary immunodeficiency and has penetrated 3-5% of its target population, with demand currently exceeding supply [3] - ADMA Biologics aims for $1.0 billion in revenue by 2030, more than doubling its projected revenue for 2024 [3] Group 3: Financial Performance - ADMA Biologics reported total revenue of $122 million in Q2 2025, reflecting a 14% year-over-year increase [4] - The stock of ADMA Biologics closed at $15.91 per share on September 19, 2025, with a market capitalization of $3.797 billion [2]

Group 1 - The core idea presented is that the Relative Strength Index (RSI) can be used to gauge market sentiment, indicating when a stock may be oversold or overbought [1] - ADMA Biologics Inc's shares have reached an RSI of 29.7, indicating they are in oversold territory, with a recent trading price of $15.14 per share [2] - The S&P 500 ETF (SPY) has a significantly higher RSI of 67.8, suggesting that ADMA's recent selling pressure may be nearing exhaustion, presenting potential buying opportunities [2][4] Group 2 - ADMA's 52-week trading range shows a low of $13.50 and a high of $25.67, with the last trade recorded at $15.30 [4]

Company Overview - ADMA Biologics is a vertically integrated U.S. Immune Globulin plasma manufacturer [1] - The company's earnings are growing due to higher finished-goods yield from each liter of plasma and a mix shift [1] Investment Strategy - The investment approach focuses on quantitative and fundamental analysis, particularly in small to mid-cap stocks [1] - A value-investing strategy is adopted, emphasizing the importance of not overpaying for stocks to mitigate risk [1] - Stocks are typically held until growth prospects diminish or the price-to-earnings ratio justifies a sale [1]

Core Insights - ADMA Biologics, Inc. is focused on developing plasma-derived biologics and has three FDA-approved products, including Asceniv, which is effective against RSV [1] Company Overview - ADMA Biologics, Inc. operates in the biopharmaceutical sector, specializing in products derived from human plasma [1] - The company has a notable product, Asceniv, which is an RSV-enriched immunoglobulin, making it particularly suitable for treating respiratory syncytial virus infections [1]

Group 1 - The article highlights ADMA Biologics, Inc. as a focus for investment discussions in 2025, particularly after a significant stock pullback following sector quarterly results [1] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [1] - The forum has seen increased interest in covered call opportunities among biotech investors in recent quarters [1] Group 2 - The article does not provide any specific financial metrics or performance data for ADMA Biologics, Inc. or the broader biotech sector [1]

Core Insights - ADMA Biologics reported better-than-expected Q2 results with adjusted earnings per share of 15 cents, beating the Zacks Consensus Estimate by a penny, and revenues of $122 million, up 14% year over year, also surpassing the estimate of $121 million [1][8] - Despite the positive results, ADMA's stock fell 7.4% in after-market trading, and year-to-date shares have decreased by 4.4% compared to the industry's growth of 0.2% [1] Financial Performance - The company's revenue growth was primarily driven by the strong adoption of its lead product, Asceniv, which contributed to a 29% year-over-year growth in underlying revenues, excluding a $12.6 million Medicaid rebate accrual reversal [6][8] - Gross margin improved to 55.1% from 53.6%, with underlying gross margin expanding by 7.7% year over year due to a favorable mix of higher-margin immunoglobulin sales and operational efficiencies [7] - Research & Development expenses increased by 84% to $1 million, while selling, general, and administrative expenses rose by 33.7% to $22.2 million [7] Product and Market Developments - ADMA's product portfolio includes three FDA-approved products: Bivigam, Asceniv, and Nabi-HB, with Asceniv being the lead product for treating primary immunodeficiency disease [4][5] - The company anticipates significant growth rates in the second half of 2025, with a revenue potential exceeding $1.1 billion from plasma products before 2030 [10][12] - ADMA is initiating SG-001, a hyperimmune globulin targeting S. pneumonia, with promising initial pilot testing results showing no clinical signs of pneumonia in treated animals [13][14] Strategic Investments - In July, ADMA completed the purchase of a $12.5 million facility adjacent to its Boca Raton manufacturing campus, enhancing its U.S.-based vertically integrated supply chain and potentially increasing future cGMP capacity by up to 30% [15]

Core Insights - Adma Biologics reported Q2 2025 earnings with total GAAP revenue of $122.0 million, exceeding analyst expectations, and a GAAP EPS of $0.14, reflecting a year-over-year growth of 7.7% [1][2][5] Financial Performance - Revenue increased by 14.0% year-over-year from $107.2 million in Q2 2024 to $122.0 million in Q2 2025, driven by strong demand for ASCENIV® [2][5] - Adjusted EBITDA reached $50.8 million, marking a 14.2% increase from Q2 2024, while adjusted net income rose to $36.0 million, up 12.3% from $32.1 million [2][7] - Gross margin improved to 55.1%, up from 53.6% in Q2 2024, attributed to higher-margin immunoglobulin sales and operational efficiencies [2][6] Operational Developments - The company initiated commercial yield enhancement in manufacturing, with early production runs showing over a 20% increase in finished IG output, which is expected to significantly impact future revenue and profit [6][10] - Strategic investments included acquiring additional manufacturing space to expand capacity by up to 30% and completing a $300 million debt refinancing to lower borrowing costs [8][10] Product and Pipeline Insights - ASCENIV and BIVIGAM therapies continued to see robust demand, with ASCENIV utilization reaching new highs [9] - The development of SG-001, a candidate hyperimmune globulin for pneumococcal infections, showed promising results in animal studies, with potential peak annual revenue estimated between $300 million and $500 million [9] Future Outlook - Management reaffirmed revenue guidance of over $500 million for fiscal 2025 and more than $625 million for 2026, with total annual revenue expected to exceed $1.1 billion before 2030 [10] - The current guidance does not fully account for the impact of the FDA-approved yield enhancement or new pipeline products, indicating further growth potential [10][11]

Core Viewpoint - Adma Biologics reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and showing an increase from $0.13 per share a year ago, indicating a positive earnings surprise of +7.14% [1] Financial Performance - The company achieved revenues of $121.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.73% and up from $107.19 million in the same quarter last year [2] - Over the last four quarters, Adma Biologics has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Adma Biologics shares have increased approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.17 on revenues of $130.7 million, and for the current fiscal year, it is $0.61 on revenues of $505.8 million [7] - The company's earnings outlook will be crucial for assessing future stock performance, especially in light of recent earnings report and management commentary [4][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8]